[go: up one dir, main page]

TW510900B - Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia - Google Patents

Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia Download PDF

Info

Publication number
TW510900B
TW510900B TW088107532A TW88107532A TW510900B TW 510900 B TW510900 B TW 510900B TW 088107532 A TW088107532 A TW 088107532A TW 88107532 A TW88107532 A TW 88107532A TW 510900 B TW510900 B TW 510900B
Authority
TW
Taiwan
Prior art keywords
bromo
dimethyl
alkyl
thiophen
acid
Prior art date
Application number
TW088107532A
Other languages
English (en)
Chinese (zh)
Inventor
Jay E Wrobel
Arlene J Dietrich
Madelene M Antane
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of TW510900B publication Critical patent/TW510900B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/74—Naphthothiophenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
TW088107532A 1998-05-12 1999-05-10 Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia TW510900B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7671298A 1998-05-12 1998-05-12

Publications (1)

Publication Number Publication Date
TW510900B true TW510900B (en) 2002-11-21

Family

ID=22133746

Family Applications (1)

Application Number Title Priority Date Filing Date
TW088107532A TW510900B (en) 1998-05-12 1999-05-10 Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia

Country Status (22)

Country Link
EP (1) EP1077969A1 (sk)
JP (1) JP2002516321A (sk)
KR (1) KR20010043539A (sk)
CN (1) CN1308626A (sk)
AR (1) AR015294A1 (sk)
AU (1) AU756337B2 (sk)
BG (1) BG104918A (sk)
BR (1) BR9911779A (sk)
CA (1) CA2330620A1 (sk)
EA (1) EA200001175A1 (sk)
EE (1) EE200000653A (sk)
HR (1) HRP20000767A2 (sk)
HU (1) HUP0101792A3 (sk)
ID (1) ID26244A (sk)
IL (1) IL139132A0 (sk)
NO (1) NO20005677L (sk)
PL (1) PL344081A1 (sk)
SK (1) SK16992000A3 (sk)
TR (1) TR200003333T2 (sk)
TW (1) TW510900B (sk)
WO (1) WO1999061435A1 (sk)
ZA (1) ZA200005961B (sk)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472545B2 (en) 2000-08-29 2002-10-29 Abbott Laboratories Protein tyrosine phosphatase inhibitors
WO2002018363A2 (en) * 2000-08-29 2002-03-07 Abbott Laboratories 3-phenyl-propanoic acid derivatives as protein tyrosine phosphatase inhibitors
AU2001292518A1 (en) * 2000-09-26 2002-04-08 Biovitrum Ab Novel compounds
US6498182B2 (en) 2000-09-26 2002-12-24 Biovitrum Ab Compounds
US6969730B2 (en) 2001-03-16 2005-11-29 Abbott Laboratories Amines as histamine-3 receptor ligands and their therapeutic applications
US6734197B2 (en) 2001-06-07 2004-05-11 Wyeth Combination therapy for type II diabetes or Syndrome X
US20020198201A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and an aldose reductase inhibitor
WO2002098407A1 (en) * 2001-06-07 2002-12-12 Wyeth COMBINATION OF A PTPase INHIBITOR AND AN ALPHA-GLUCOSIDASE INHIBITOR
US20030022896A1 (en) * 2001-06-07 2003-01-30 Wyeth PTPase inhibitors for improving cardiovascular risk profile
US20020198203A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and a thiazolidinedione agent
US6797693B2 (en) 2001-06-07 2004-09-28 Wyeth Methods using PTPase inhibitors and insulin
WO2002098410A1 (en) * 2001-06-07 2002-12-12 Wyeth Combination of a ptpase inhibitor and a sulfonylurea agent
WO2002100397A1 (en) * 2001-06-07 2002-12-19 Wyeth COMBINATION OF A PTPase INHIBITOR AND AN ANTILIPEMIC AGENT
WO2002100398A1 (en) * 2001-06-07 2002-12-19 Wyeth Combination of a ptpase inhibitor and an ace inhibitor
DE60221391T2 (de) 2001-06-20 2008-04-17 Wyeth Substituierte indolsäurederivate als inhibitoren von plasminogen-aktivator-inhibitor-1 (pai-1)
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
EP1438044A1 (en) 2001-10-19 2004-07-21 Transtech Pharma, Inc. Bis-heteroaryl alkanes as therapeutic agents
EP1443919A4 (en) 2001-11-16 2006-03-22 Bristol Myers Squibb Co DOUBLE INHIBITORS OF THE FATTY ACID BINDING PROTEIN OF THE ADIPOCYTES AND THE FATTY ACID BINDING PROTEIN OF KERATINOCYTES
EP1452530A4 (en) 2001-12-03 2005-11-30 Japan Tobacco Inc AZOL CONNECTION AND THEIR MEDICAL USE
ITMI20022172A1 (it) * 2002-10-14 2004-04-15 Clariant Lsm Italia Spa Processo per la preparazione di 3-alchil-tiofeni-2, 5-disostituiti.
MXPA05006287A (es) 2002-12-10 2005-09-08 Wyeth Corp Derivados de acido indoloxo-acetilaminoacetico sustituidos como inhibidores del inhibidor del activador de plasminogeno 1 (pai-1).
ES2314289T3 (es) 2002-12-10 2009-03-16 Wyeth Derivados del acido 1h-indol-3-il glioxilico sustituidos con arilo, ariloxi y alquloxi como inhibidores del inhibidor del activador del plasminogeno-1(pai-1).
CN1723197A (zh) 2002-12-10 2006-01-18 惠氏公司 作为纤溶酶原激活物抑制剂－1(pai－1)的抑制剂的取代3－烷基和3－芳基烷基1h－吲哚－1－基乙酸衍生物
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
MXPA05006288A (es) 2002-12-10 2005-08-19 Wyeth Corp Derivados del acido 3-carbonil-1h-indol-1-ilacetico sustituidos como inhibidores del inhibidor del activador de plasminogeno 1 (pai-1).
JPWO2004106542A1 (ja) 2003-05-29 2006-07-20 三共株式会社 インスリン抵抗性改善剤及びそのスクリーニング方法
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7420083B2 (en) 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7435837B2 (en) 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
FR2862645B1 (fr) * 2003-11-20 2007-06-22 Merck Sante Sas Composes antidiabetiques contenant des derives benzofuranes, benzothiophenes
AU2005277139A1 (en) 2004-08-23 2006-03-02 Wyeth Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1
AU2005277137A1 (en) 2004-08-23 2006-03-02 Wyeth Pyrrolo-naphthyl acids as PAI-1 inhibitors
WO2006023865A1 (en) 2004-08-23 2006-03-02 Wyeth Oxazolo-naphthyl acids as plaminogen activator inhibtor type-1 (pai-1) modulators useful in the treatment of thrombosis and cardiovascular diseases
WO2007022321A2 (en) 2005-08-17 2007-02-22 Wyeth Substituted indoles and use thereof
CA3089569C (en) 2007-06-04 2023-12-05 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
GB0822486D0 (en) * 2008-12-10 2009-01-14 Univ Liverpool Compounds for use in the treatment of pain
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9486433B2 (en) 2012-10-12 2016-11-08 Mochida Pharmaceuticals Co. Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
EP2968245B1 (en) 2013-03-15 2021-05-05 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
ES2981866T3 (es) 2013-06-05 2024-10-10 Bausch Health Ireland Ltd Agonistas ultrapuros de guanilato ciclasa C, método de elaboración y uso de los mismos
CN106749169B (zh) * 2016-11-07 2020-04-21 浙江工业大学 一种Ertiprotafib的手性制备方法
CN107033122B (zh) * 2017-05-19 2019-06-14 南方医科大学 一种n-芳基-2-噻吩酰胺类衍生物及其制备方法和用途
US20210115397A1 (en) 2018-04-26 2021-04-22 Tokyo Institute Of Technology Method for promoting differentiation of pluripotent stem cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2015724B1 (sk) * 1968-08-15 1973-01-12 Parke Davis & Co
US3639422A (en) * 1969-07-28 1972-02-01 Parke Davis & Co 4-phenylindole-1 (and 7)-acetic acids
US3682976A (en) * 1970-02-16 1972-08-08 Parke Davis & Co Phenyl benzofuran acetic acid compounds
GB8417559D0 (en) * 1984-07-10 1984-08-15 Pfizer Ltd Anti-diarrhoeal agents
FR2599740B1 (fr) * 1986-06-05 1988-08-12 Rhone Poulenc Sante Derives de benzo(b)thiophene de benzo(b)furannecarboxamides, leurs procedes de preparation et les medicaments les contenant
JPH01135766A (ja) * 1987-11-20 1989-05-29 Tanabe Seiyaku Co Ltd ビフェニル誘導体
US5110825A (en) * 1989-12-28 1992-05-05 Shionogi & Co., Ltd. Benzofuran derivative
US5340833A (en) * 1992-05-01 1994-08-23 Eisai Co., Ltd. Urokinase inhibitors
DE4425613A1 (de) * 1994-07-20 1996-01-25 Bayer Ag 5-gliedrige Heteroaryl-oxazolidinone

Also Published As

Publication number Publication date
PL344081A1 (en) 2001-09-24
HRP20000767A2 (en) 2001-10-31
AU756337B2 (en) 2003-01-09
KR20010043539A (ko) 2001-05-25
EE200000653A (et) 2002-04-15
JP2002516321A (ja) 2002-06-04
NO20005677L (no) 2000-12-05
EP1077969A1 (en) 2001-02-28
BR9911779A (pt) 2001-02-06
EA200001175A1 (ru) 2001-06-25
ZA200005961B (en) 2001-10-24
SK16992000A3 (sk) 2001-04-09
HUP0101792A2 (hu) 2002-01-28
AU3893999A (en) 1999-12-13
CA2330620A1 (en) 1999-12-02
HUP0101792A3 (en) 2003-01-28
AR015294A1 (es) 2001-04-18
CN1308626A (zh) 2001-08-15
BG104918A (bg) 2001-08-31
WO1999061435A1 (en) 1999-12-02
TR200003333T2 (tr) 2001-02-21
NO20005677D0 (no) 2000-11-10
ID26244A (id) 2000-12-07
IL139132A0 (en) 2001-11-25

Similar Documents

Publication Publication Date Title
TW510900B (en) Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia
EP1519915B1 (en) Tricyclic steroid hormone nuclear receptor modulators
US7005538B1 (en) Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
US12006290B2 (en) Crystalline norpsilocin compounds
US11926590B2 (en) Crystalline 4-hydroxy-N,N-di-n-propyltryptammonium (4-HO-DPT) salts
TW446704B (en) Naphtho[2,3-B]heteroar-4-yl derivatives for treating metabolic disorders related to insulin resistance or hyperglycemia
KR101708073B1 (ko) 록소프로펜 유도체 및 그것을 함유하는 의약
KR100250922B1 (ko) 교감신경 흥분 및 항빈뇨 활성을 갖는 에탄올아민 유도체
CN104109115B (zh) 一种含氮杂环链接的苯丙酸类化合物、其药物组合物、制备方法和用途
BR112013000783A2 (pt) derivados arilamídicos tendo propriedades antiandrogênicas
Al-Ostoot et al. Molecular docking and synthesis of caffeic acid analogous and its anti-inflammatory, analgesic and ulcerogenic studies
AU2006244709A1 (en) Benzoic acid derivatives that are modulators or agonists of GLYR
AU2002331145B2 (en) Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
JPH01190688A (ja) ピロリチジン化合物およびその用途
Khadri et al. Synthesis, analgesic, anti-inflammatory, ulcerogenic evaluation, and docking study of (benzoylphenoxy)-N-{5-[2-methylphenyl-6-chlorobenzoxazole]} acetamides as COX/5-LOX inhibitor
CA3018801C (en) Substituted-indole compounds as estrogen receptor down-regulators
US9351980B2 (en) Di-aspirin derivatives
JP2021523934A (ja) ミトコンドリア脱共役剤として有用なアミノピラジンおよび関連化合物
WO2015055114A1 (zh) 二苯乙烷衍生物及其应用
CN112574172B (zh) 一种没食子酸硫化氢衍生物及其制备方法及医药用途
CN102250138A (zh) 一种杂氮锗三环类化合物及其制备方法和应用
FI78898C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 4-hydroxi- -etylbenshydrolderivat.
US20090270470A1 (en) Compounds I
JPH02279660A (ja) テトラヒドロナフタレン誘導体
US20120095048A1 (en) Allosteric binding compounds